You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 43 No. 4, April 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Dopaminergic Effects of Carbamazepine

Relationship to Clinical Response in Affective Illness

Robert M. Post, MD; David R. Rubinow, MD; Thomas W. Uhde, MD; James C. Ballenger, MD; Markku Linnoila, MD, PhD

Arch Gen Psychiatry. 1986;43(4):392-396.


Abstract

• Carbamazepine, a drug used widely to treat epilepsy and trigeminal neuralgia, has been shown to be effective in the acute and prophylactic treatment of manic-depressive illness. While the time course of its antimanic effects parallels that of classic neuroleptics, indirect clinical evidence, such as lack of parkinsonian side effects and tardive dyskinesia, suggests that carbamazepine does not act by blocking dopamine receptors. To assess the effects of carbamazepine on dopamine mechanisms, we measured the dopamine metabolite homovanillic acid (HVA) in the cerebrospinal fluid of affectively ill patients before and after treatment. Carbamazepine did not alter basal concentrations of HVA, but decreased probenecidinduced accumulations of HVA, paralleling results in animal studies. In 25 patients, lower baseline cerebrospinal fluid HVA levels were related to subsequent better acute antidepressive responses to carbamazepine. While the precise mechanism of carbamazepine's effects on dopaminergic systems remains to be determined, this study provides further evidence that carbamazepine does not have a biochemical profile typical of neuroleptics.



Author Affiliations

From the Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Md (Drs Post, Rubinow, and Uhde); Department of Psychiatry and Behavioral Medicine, University of South Carolina, Charleston (Dr Ballenger); and the Laboratory of Clinical Studies, National Institute of Alcohol Abuse and Alcoholism, Bethesda, Md (Dr Linnoila).


Footnotes

Accepted for publication Feb 25, 1985.

Reprint requests to Biological Psychiatry Branch, National Institute of Mental Health, Room 3N212, Bldg 10, 9000 Rockville Pike, Bethesda, MD 20205 (Dr Post).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.